{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013644","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.180083+00:00","generated_at":"2026-06-15T05:55:24.983223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K","bullets":["Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.","Cash and securities $11.8M at Mar 31, 2023, down from $12.7M at Dec 31, 2022.","Received ~$1.27M from sale of minority stake in Alphazyme in Jan 2023.","DYAI-100 booster vaccine dosing completed; no serious adverse events; safety report due June 2023.","Expanded collaborations with Rubic One Health (Africa) and new top-5 pharma research."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013644","json":"https://secwatch.observer/filing/0001437749-23-013644.json","markdown":"https://secwatch.observer/filing/0001437749-23-013644.md","text":"https://secwatch.observer/filing/0001437749-23-013644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/0001437749-23-013644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/dyai20230125_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:55:24.983223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79087c7b19f0f9179676d89b53c15c535980d602","claim":"DYADIC INTERNATIONAL INC reported financial results for quarter ended March 31, 2023.","evidence_excerpt":"Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/0001437749-23-013644-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}